Arbaclofen extended-release (ER) reduced spasticity in patients with multiple sclerosis and was found to be safe and well-tolerated, according to 2 new abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers.
“Spasticity is common in patients with MS and associated with significant morbidity. The standard treatment is oral baclofen, a γ-aminobutyric acid-b receptor agonist. Baclofen is a racemic mixture while arbaclofen is the more active R-enantiomer,” researchers said. “Therapeutic doses of baclofen may cause side effects and decreased adherence arbaclofen ER tablets allow for twice-daily administration, reducing dosing frequency, and may reduce adverse events (AEs) in some patients.”